CTNNB1 and hemoglobin measurement: Exome sequencing of primary HB not only demonstrated an unexpectedly low mutation rate, with an average of only 2.9 mutations per tumor (6), but also confirmed that CTNNB1 mutations and deletions were present in 78 out of 88 (89%) of the tumors examined (7).